Drug company outsource probe sought

Share this article:
Sen. Sherrod Brown (D-OH) wants the FDA to evaluate how it protects the American public from drug products containing tainted, outsourced ingredients. Brown says that in a recent Senate committee hearing, FDA director of drugs, Janet Woodcock, testified that US drug companies outsource operations to take advantage of weaker drug safety standards in some foreign countries. 

In a subsequent letter to Woodcock, Brown asked her to provide the volume of pharmaceutical ingredients outsourced by US drug manufacturers to China and other countries with weaker drug safety regimes than that of the US and the incremental annual cost of protecting the public from tainted pharmaceutical ingredients produced in countries without drug safety regimes comparable to those in the US. He also asked Woodcock for her opinion on the best means for the FDA to hold accountable drug companies that outsource ingredient production.

“It is no coincidence that drug ingredients produced in countries with weak safety standards are often contaminated,” Brown said. “FDA must immediately review pharmaceutical outsourcing and make necessary changes to keep American consumers safe.” Brown also wrote to Pfizer VP of quality Gerald Migliaccio, who testified before the same Senate committee as Woodcock, that 17% of Pfizer's active ingredients and drug product manufacturing are outsourced.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?